Form 4: Benitec Biopharma Inc. Executive Granted Stock Options

Benitec Biopharma Inc. grants stock options to executive Edward Smith, vesting upon the next annual stockholders' meeting or December 9, 2025.

Summary

• Benitec Biopharma Inc. has granted stock options to executive Edward Smith.
• The options are for 35,000 shares of common stock.
• The exercise price of the options is $12.18 per share.
• The options will vest on the earlier of the company's next annual stockholders' meeting or December 9, 2025.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock options granted to an executive, which is generally a positive sign for aligning management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The granting of stock options can serve as an incentive for executive performance.
• The vesting period aligns executive interests with the long-term success of the company.

Risks

• The value of the options is dependent on the future performance of the company's stock price.
• There is a risk that the stock price may not reach the exercise price of $12.18 before the options expire.

Future Outlook

The vesting of the options is contingent on the company's next annual stockholders' meeting or December 9, 2025, whichever comes first.

Industry Context

Granting stock options is a common practice in the biotechnology industry to attract and retain key executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often used to incentivize performance and align interests with shareholders.
• The vesting period of the options is typical, often tied to specific dates or performance milestones.
• The exercise price of $12.18 per share would need to be compared to the current market price of the stock to determine if it is at, above, or below market value.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for executive performance.
• The executive, Edward Smith, is incentivized to improve the company's performance to increase the value of his options.

Next Steps

• The company will hold its next annual stockholders' meeting.
• The options will vest on the earlier of the next annual stockholders' meeting or December 9, 2025.

Key Dates

Keywords

stock options, executive compensation, vesting, common stock, Benitec Biopharma